Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu
© Borgis - Postępy Nauk Medycznych 12/2013, s. 891-895
Agnieszka Jamrozy-Witkowska1, Anna Uliasz1, Ewa Czaplicka2, *Iwona Grabska-Liberek1
Orbitopatia tarczycowa
Thyroid associated orbithopathy
1Clinic of Ophthalmology, Medical Center of Postgraduate Education, Warszawa
Head of Clinic: Iwona Grabska-Liberek, MD, PhD, assoc. prof.
2Department and Clinic of Ophthalmology, Poznań University of Medical Sciences
Head of Department and Clinic: Jarosław Kocięcki, MD, PhD
Oftalmopatia tarczycowa (w przeszłości choroba była nazywana także oftalmopatią Gravesa-Basedowa) jest chorobą autoimmunologiczną, w przebiegu której dochodzi do immunologicznego zapalenia mięśni, tkanki tłuszczowej i łącznej wypełniającej oczodół. Etiologia zmian ocznych w przebiegu choroby nie jest do końca poznana. Podkreśla się jej autoimmunologiczny charakter, występowanie wspólnego antygenu w komórkach nabłonka pęcherzykowego tarczycy i fibroblastach oczodołów. Choroba występuje częściej u kobiet, a szczyt zachorowań przypada między 30. a 60. rokiem życia, należy jednak pamiętać, że cięższe przypadki zachorowań występują z większą częstością u mężczyzn. Objawy oczne pojawiające się w przebiegu tego schorzenia to m.in. wytrzeszcz, obrzęk spojówek, obrzęk mięska łzowego zaczerwienienie powiek, obrzęk wokół oczu, zmniejszona ruchomość gałek ocznych, czy pogorszenie ostrości widzenia. Objawy oczne mogą być różnorodne, od zmian o charakterze łagodnym, które często zostają przeoczone i mają tendencję do samoistnego ustępowania, aż po zmiany o charakterze ciężkiej naciekowej oftalmopatii. Celem pracy jest przedstawienie i analiza aktualnej wiedzy na temat tej jednostki chorobowej – stanowiącej współcześnie diagnostyczne i terapeutyczne wyzwanie, z uwzględnieniem patogenezy, objawów klinicznych i metod leczenia.
Graves’ orbithopathy, frequently termed thyroid-associated orbitopathy an autoimmune disorder characterized by orbital inflammation involving both extra-ocular muscles and adipose tissue. Inappropriate immune reactions averse to the orbital antigens and damage of immune tolerance are probably involved in its pathogenesis. It is characterized by a wide open orbit appearance, caused by exophthalmus and upper eyelid retraction, occurs far more often in women than in men and is most prevalent between 30 and 60 years of age, however severe cases occur more often in men than in women. The ocular manifestations of thyroid-associated orbitopathy include also chemosis, proptosis, periorbital edema, as well as altered ocular motility with significant functional cosmetic or social consequences. The clinical manifestation may vary – from mild disease when it may be overlooked and misdiagnosed to severe irreversible sight-threatening complications. Although most cases of Graves’ orbithopathy do not result in visual loss, this disease can cause vision-threatening exposure keratopathy, troublesome diplopia or even compressive optic neuropathy. The present article summarize pathogenesis, clinical manifestations, and treatment of this so far poorly understood disorder, which is a problematic challenge to the ophthalmologist.

Graves’ orbithopathy (GO, thyroid ophthalmopathy, thyroid eye disease, thyroid-related ophthalmopathy, orbitopathy) is an autoimmune, chronic, debilitating infiltrative eye disorder, which affects the orbit and eyelids. It is often connected with thyroid pathology. Generally it appears in patients with active or treated Graves’ disease or uncommonly with Hashimoto’s thyroiditis (HT) or even among euthyroid patients. Grave’s ophthalmopathy could be disfiguring and potentially severely disabling because of ocular suffering, as well as its influence on vision and appearance. GO influences orbital tissues in 25-50% of patients with Graves’ disease (1-3). On the other hand about 5% of patients with autoimmune thyroiditis or without clinically evident thyroid disease will develop Graves’ ophthalmopathy (4-6). It is diagnosed most commonly in women with female-to-male ratio of 5:1 and with peak occurrence of onset between the ages of 30 and 60 years, much less common in children than in adults (7). GO patients are older than patients with Graves’ hyperthyroidism without orbitopathy. The annual incidence of TAO in the general population is 16.0 per 100 000 population for women and 3 per 100 000 population for men with severe forms accounting for no more than 3-5% of the cases. Although GO is unquestionably more common in women, statistically, severe cases are slightly more common in men. The female to male ratio was 9.3:1 in patients with mild Graves’ orbithopathy, 3.2:1 in those with moderate orbitopathy, and 1.4:1 with severe cases. The severity and incidence of GO depends not only on the gender but it also appears to be significantly higher among smokers compared with nonsmokers (8, 9). Furthermore, cigarette smoking is one of the strongest modifiable risk factor for developing GO. It not only increases the risk of developing Graves’ ophthalmopathy, but also increases its severity and progression with a less beneficial response to therapy. Recently studies reported higher risk for prevalence of GO in patients with hyperthyroidism in Europeans compared to Asians (10). Bartalena at al. and some others researchers investigated relation between the therapy of hyperthyroidism due to Graves’ disease and the course of Graves’ orbitopathy. They showed that that radioiodine therapy for Grave’s disease was followed by the development or more often, the evolution of ophthalmopathy. Otherwise, the patients treated with thionamides or with radioiodine and prednisone had no progression of eye disease. The development of ophthalmopathy after radioiodine therapy could be related with liberate of thyroid antigens as an effect of radiation injury leading to stimulation of autoimmune reactions directed to antigens shared by the thyroid and the orbit. In addition, the post-treatment hypothyroidism is crucial in the development of ophtalmopathy (3, 11).
Although the pathogenic mechanism of Graves’ ophthalmopathy (GO) is still unknown, there is significant evidence for autoimmune reactions directed to orbital antigens, in particular to extraocular muscles, orbital fat, interstitial tissues or lacrymal glands which increase the volume of the orbital contents. Probably Graves’ orbitopathy is induced by an autoimmune reaction against antigens shared by orbital and thyroid fibrous and adipose tissues. The orbital autoantigen has not been conclusively identified but the most popular candidate antigen is the TSH receptor (TRAb) since GO is frequently connected with Graves’ disease and anti-TSH-receptor autoantibodies are founded in nearly 100% of patients with Graves’ orbitopathy. TRAb transcripts were presented by northern blot in orbital adipose tissue from a patient with GO, whereas transcripts in normal adipose tissue being at the limit of the detection (12-16). Recently many researchers and clinicians accepted that TRAb titers and prevalence correlate with the severity and activity of GO (14). It is known that orbital fibroblasts, which present the TSH receptor, are major participants in the pathogenesis of Graves’ ophthalmopathy. Firstly, T lymphocytes are activated by unknown mechanisms and then transit to the thyroid gland, orbit and eyelids. Subsequently, activated T lymphocytes produce cytokines to affect inflammation, local fibroblast activation and expansion of adipose tissue via cellular metaplasia. Activated orbital fibroblasts produce chemokines that recruit T lymphocytes into the orbit. These lymphocytes then cooperate with fibroblasts, probably activating each other. There is increasing evidence that orbital fibroblasts alone and interacting with lymphocytes can release excessive amounts of the of glycosaminoglycans, hyaluronic acid, chondroitin sulfate and finally collagen upon stimulation with various cytokines. In this scenario throglobulin, the TSH receptor, insulin-like growth factor-1 receptor (IGF-1R) or B cells have all been implicated. Inflammation targeted at the extraocular muscles as well as periocular tissues consists of lymphocytes, mast cells, and plasma cells. The histological changes are due to the accumulation of hydrophilic glycosaminoglycans, predominantly hyaluronan, and an increase in orbital adipose and connective tissue. Graves’ ophthalmopathy begins as an active phase (inflammatory phase) followed by partial regression of symptoms which eventually leads to spontaneously remission (inactive phase, static stage) (4, 5). The different clinical signs of active GO are induced by inflammatory processes of retroocular adipose/connective tissue with infiltration of type 1 helper T (Th1) cells but also plasma cells, B cells, mast cells or macrophages. The demonstrate of primarily Th1 cells and connected cytokines (Interferon-gamma [IFN-γ], tumour necrosis factor [TNF], interleukin-2) in early disease indicates that cell-mediated immunity predominates in initial disease. On the other hand in later phases of Graves’ ophthalmopathy predominate Th2 cells and cytokines (interleukin-5, interleukin-4, interleukin-10 and interleukin-13) which stimulating B-cells to produce autoantibodies. Accelerated production of glycosaminoglycans induces an edematous expansion of orbital connective tissue that effects in dysfunction of changed muscles like disturbances in ocular motility, increased orbital pressure and even displacement of the eye (proptosis) (6-8).
The histological changes explain the clinical manifestations of Graves’ orbitopathy which can be variable: exophthalmos, lagophthalmos (inability to close the eye), eyelid retraction, corneal exposure, periorbital and lid edema, edema of the bulbar conjunctivae, palpebral and conjunctival redness, chemosis, epiphora, photophobia, inflamed caruncle, visual changes (visual field defects, reduced visual acuity, reduced color sensitivity), orbital pain, diplopia (most commonly on up-gaze) or strabismus. They may also include loss of eyelashes and eyebrows, dermatochalazia or conjunctival injection. Superior limbic keratoconjunctivitis is known as a prognostic marker for severe disorder (9).

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. Park JJ, Sullivan TJ, Mortimer RH et al.: Assesing quality of life in Australian patients with Graves’ ophthalmopathy. Br J Ophthalmol 2004; 88: 75-78.
2. Jankauskiene J, Imbrasiene D: Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves’ ophthalmopathy. Medicina (Kaunas) 2006; 42: 11.
3. Bartalena L, Marcocci C, Bogazzi F et al.: Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 8(338): 73-78.
4. Marcocci C, Pinchera A, Marinò M: A treatment strategy for Graves’ orbitopathy. Nat Clin Pract Endocrinol Metab 2007; 3: 430-436.
5. Soeters MR, van Zeijl CJ, Boelen A et al.: Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 2011; 69: 302-308.
6. Kuriyan AE, Phipps RP, Feldon SE: The eye and thyroid disease. Curr Opin Ophthalmol 2008; 19: 499-506.
7. Kubo T, Shimizu J, Furujo M et al.: An infant case of Graves’ disease with ophthalmopathy. Endocr J 2005; 52: 647-650.
8. Alsuhaibani A, Jeffrey A: An infant case of Graves’ disease with ophthalmopathy. Endocr J 2005; 52: 647-650.
9. Gould D, Roth-Charles F, Soparkar Ch: The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy. Aesth Plast Surg 2012; 36: 638-648.
10. Maheshwari R, Weis E: Thyroid associated orbitopathy. Indian J Ophthalmol 2012; 60: 87-93.
11. Tallstedt L, Lundell G, Torring O et al.: Occurrence of ophthalmology after treatment for Grave’hiperthyroidism. N Engl J Med 1992; 326: 1733-1738.
12. Hiromatsu Y, Tanaka K, Sato M et al.: Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J 1993; 40: 63-72.
13. Stiglmayer N, Mladina R, Tomić M et al.: Endonasal Endoscopic Orbital Decompression in Patients with Graves’ Ophthalmopathy. Croat Med J 2004; 45: 318-322.
14. Eckstein A, Plicht M, Lax H et al.: Thyrotropin Receptor Autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. JCEM 2006; 91: 3464-3470.
15. Boschi A, Daumerie Ch, Spiritus M et al.: Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol 2005; 89: 724-729.
16. Drexhage HA: Are there more than antibodies to the thy-roid-stimulating hormone receptor that meet the eye in Graves’disease? Endocrinology 2006; 147: 9-12.
17. McKeag D, Lane CM, Lazarus JH et al.: Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007; 91: 455-458.
18. Estcourt S, Quinn AG, Vaidya B et al.: Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol 2011; 164: 649-655.
19. Mourits MP, Koornneef L, Wiersinga WM et al.: Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639-644.
20. European Group on Graves' Orbitopathy (EUGOGO), Perros P, Baldeschi L et al.: A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 2006; 155: 207-211.
21. Wiersinga WM, Perros P, Kahaly GJ et al.: Clinical assessment of patients with Graves’orbitopathy: the European Group on Graves’ orbitopathy rec-ommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006; 155: 387-389.
22. Prummel MF, Bakker A, Wiersinga WM et al.: Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 2003; 148: 491-495.
23. Marcocci C, Kahaly GJ, Krassas GE et al.: Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364: 1920-1931.
24. Kahaly GJ, Pitz S, Hommel G et al.: Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 2005; 90: 5234-5240.
25. Marcocci C, Bartalena L, Tanda ML et al.: Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86: 3562-3567.
26. Bartalena L, Baldeschi L, Dickinson AJ et al.: Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008; 18: 333-346.
27. Salvi M, Vannucchi G, Campi I et al.: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156: 33-40.
28. Ebner R, Devoto MH, Weil D et al.: Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004; 88: 1380-1386.
29. Prummel MF, Terwee CB, Gerding MN et al.: A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab 2004; 89: 15-20.
30. Marcocci C, Bartalena L, Rocchi R et al.: Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 2003; 88: 3561-3566.
31. Kahaly GJ, Rösler HP, Pitz S et al.: Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000; 85: 102-108.
32. Sellari-Franceschini S, Muscatello L, Seccia V et al.: Reasons for revision surgery after orbital decompression for Graves’ orbitopathy. Clin Ophthalmol 2008; 2: 283-290.
33. Kalmann R, Mourits MP, van der Pol JP et al.: Coronal approach for rehabilitative orbital decompression in Graves’ ophthalmopathy. Br J Ophthalmol 1997; 81: 41-45.
34. Elner VM, Hassan AS, Frueh BR: Graded full-thickness anterior blepharotomy for upper eyelid retraction. Arch Ophthalmol 2004; 122: 55-60.
35. Paridaens D, Lie A, Grootendorst RJ et al.: Efficacy and side effects of ‘swinging eyelid’ orbital decompression in Graves’ orbitopathy: a proposal for standardized evaluation of diplopia. Eye (Lond) 2006; 20: 154-162.
otrzymano: 2013-09-22
zaakceptowano do druku: 2013-11-04

Adres do korespondencji:
*Iwona Grabska-Liberek
Clinic of Ophthalmology
Medical Center of Postgraduate Education
Prof. W. Orłowski Independent Public Clinical Hospital
ul. Czerniakowska 231, 00-416 Warszawa
tel./fax: +48 (22) 629-71-09
e-mail: kl.okulistyki@szpital-orlowskiego.pl

Postępy Nauk Medycznych 12/2013
Strona internetowa czasopisma Postępy Nauk Medycznych